Skip to main content

Advertisement

Table 1 Clinical information of completer (n = 11) and all randomized patients (n = 20, completer and drop-outs)

From: Feasibility of whole body vibration during intensive chemotherapy in patients with hematological malignancies – a randomized controlled pilot study

  Completer All
IG n = 6 CG n = 5 n = 20
Age [years]a 47 (19–62) 56 (32–63) 55 (47–63)
Sex [n] male:female 5:1 3:2 14:6
BMI [kg/m2]a 26 (20–28) 26 (22–28) 26 (25–27)
Diagnosis [n]
 AML 1 4 8
 ALL 1 0 1
 APL 1 0 1
 NHL 2 0 5
 HL 0 0 1
 t-cell lymphoma 1 0 1
 MW 0 0 1
 MM 0 1 1
 PMF 0 0 1
Remission [n]
 ED 1 3 7
 SD 0 1 2
 PD 1 0 1
 CR 0 1 2
 PR 0 0 1
 recurrence 2 0 5
 N/A 2 0 2
Time since initial diagnosis [weeks]a 46 (2–371) 6 (2–215) 32 (7–128)
Cycles of chemotherapy before admission [n]a 9 (0–16) 1 (0–9) 4 (1–9)
Type of chemotherapy during intervention [n]
 High-dose prior to autologous HSCT 1 1 5
 Induction therapy for AML 4 3 8
 Intensive chemotherapy for ALL, HL, NHL 1 1 7
Duration of hospitalization [days]a 27 (21–56) 27 (16–69) 26 (22–34)
Karnofsky performance index [%]a 95 (80–100) 90 (80–100) 90 (85–90)
  1. aMedian (range), BMI body mass index, AML acute myeloid leukemia, ALL acute lymphocytic leukemia, APL acute promyelocytic leukemia, NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, MW morbus Waldenström, MM multiple myeloma, PMF primary myelofibrosis, ED initial diagnosis, SD stable disease, PD progress disease, CR complete remission, PR partial remission, HSCT hematopoietic cell transplantation